ExpreS2ion Biotechnologies and the Jenner Institute, University of Oxford Enter a Licensing Agreement
Complete the form below to unlock access to ALL audio articles.
ExpreS2ion Biotechnologies has announced that they have signed a research license agreement to provide the University of Oxford access to ExpreS2ion's Drosophila Schneider-2 cell-based technology platform - ExpreS2 - for protein production.
The stable, non-lytic protein expression platform, which is fully cGMP compatible, will complement the existing capabilities in protein vaccine expression at the Jenner Institute, University of Oxford.
The platform will be used by various research teams to address expression of complex and "difficult-to-make" proteins.
This license is a perfect example of ExpreS2ion Biotechnologies' vision of making its production platform available to academic centers of excellence globally, in complement to the Company's strategy of making S2 one of the standard protein production platforms in the vaccine and therapeutic protein segments.
Dr. Charlotte Dyring, CEO of ExpreS2ion Biotechnologies, said: "We are delighted that the Jenner Institute at Oxford University has taken a Research License to our proprietary ExpreS2 platform for protein expression. The ExpreS2 platform has shown to provide a way forward to projects with a need for a robust and fully scalable protein production platform, such as certain challenging recombinant subunit vaccine projects.
ExpreS2ion is proud to enter this Agreement with the University of Oxford, one of the world's most prestigious Universities, with well-established, world-recognized medical research."
Dr. Simon Draper, a MRC Research Fellow, commented: "access to the ExpreS2 platform at the Jenner Institute in Oxford will greatly expand our protein vaccine production capabilities. We are looking forward to working with ExpreS2ion Biotechnologies as we develop new clinically-relevant protein vaccines to target difficult pathogens, such as malaria."
